Nuvilex Inc., TD2 and the PCRT Should Draw Great Interest to the Company's Pancreatic Cancer Treatment
June 20 2014 - 9:00AM
Marketwired
Nuvilex Inc., TD2 and the PCRT Should Draw Great Interest to the
Company's Pancreatic Cancer Treatment
NEW YORK, NY--(Marketwired - Jun 20, 2014) - Nuvilex, Inc.
(OTCQB: NVLX) can accomplish more in its upcoming preclinical
trials than many may realize. With the announcement that
Translational Drug Development (TD2) will be conducting the
preclinical studies and clinical trials that will follow to study
the Maryland biotech's pancreatic cancer treatment and its ability
to relieve symptoms associated with the deadly cancer, Nuvilex
entered into a high profile opportunity.
TD2 is considered by many to be the premiere Contract Research
Organization (CRO) in the country when it comes to oncology studies
and trials, so when Nuvilex begins its preclinicals, you can bet
Cell-in-a-Box® will be front and center, and for the first time
ever, it will get the true attention it deserves.
While most of the company's investors are waiting on late phase
clinical trials in advanced pancreatic cancer to begin, the company
stated it would be entering into another area of research in
pancreatic cancer as well -- to relieve the unbearable pain
associated with the cancer and to slow the onset and build-up of
ascites fluid caused by pancreatic cancer and other abdominal
cancers in the abdominal cavity.
This exposure for Nuvilex and the company's treatment of
Cell-in-a-Box® combined with the anticancer drug ifosfamide will be
invaluable. TD2 is a world-class drug development service,
specializing in getting the newest and best oncology treatments to
cancer patients as quickly as possible. Additionally, the firm
is associated with the Pancreatic Cancer Research Team (PCRT) which
gives Nuvilex access to the world's clinical experts in pancreatic
cancer.
TD2's work garners a great deal of attention, and its results
are well documented. This is likely due to the fact that the
Scottsdale, Arizona, CRO and the PCRT are made up of some of the
most well-known names in oncology.
The PCRT was created by world-renowned pancreatic cancer experts
Dr. Daniel Von Hoff and Dr. Manuel Hidalgo. The consortium of
experts is a premiere resource for biotech and pharmaceutical
companies looking to develop new agents for patients with
pancreatic cancer. This network provides the world's most
coordinated effort dedicated to rapidly translating research
discoveries into new treatments and supportive care.
And, one has to believe that if the Cell-in-a-Box®/ifosfamide
combination can prove itself to such an impressive and influential
group of clinicians, word will spread quickly of its
potential. It could very well be this exposure that draws even
greater interest to Nuvilex's treatment, its late phase clinical
trials and the catalyst behind forming potential relationships and
partnerships that could allow the company to get an effective
pancreatic treatment to market in expedited fashion.
About Stock Market Media Group SMMG is a Research and Content
Development IR firm offering a platform for corporate stories to
unfold in the media with Reports, Interviews and Articles. SMMG is
compensated for Nuvilex content by a third party who reserves the
right to buy, sell or remain neutral on securities after the
publication of this article. SMMG has received total compensation
of $99,700 for all created content related to Nuvilex.
Additionally, a principal at SMMG currently owns 200,000 total
shares of Nuvilex issued by the company through a consulting
agreement which has since ended for work unrelated to content
development. All shares have been held for the requisite period
under Rule 144 as of April 30, 2014, and are eligible to be sold
immediately without further notice. For more information:
www.stockmarketmediagroup.com.
Contact: Stock Market Media Group Email Contact